These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 21546048)

  • 21. [Comparison of early virologic response among patients with chronic hepatitis C infected with genotype non 2/3 treated with pegylated interferon alfa-2B and ribavirin in dependence with hepatic fibrosis stages].
    Berak H; Kołakowska-Rzadzka A; Wasilewski M; Stańczak JJ; Krzysztof B; Walewska-Zielecka B; Horban A
    Przegl Epidemiol; 2006; 60(4):673-6. PubMed ID: 17682747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
    Pearlman BL; Ehleben C; Perrys M
    Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
    Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
    Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.
    Hu CC; Lin CL; Kuo YL; Chien CH; Chen SW; Yen CL; Lin CY; Chien RN
    Aliment Pharmacol Ther; 2013 Jan; 37(1):81-90. PubMed ID: 23121150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early virological response in 1220 patients with HCV (genotype lb) chronic hepatitis and cirrhosis treated with PegInterferon plus Ribavirin.
    Pascu O; Voiculescu M; Gheorghe L; Micu L; Seicean A; Iliescu L; Mocan T; Ceauşu E; Mateescu B
    Rom J Intern Med; 2011; 49(2):105-12. PubMed ID: 22303601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
    Reddy KR; Zeuzem S; Zoulim F; Weiland O; Horban A; Stanciu C; Villamil FG; Andreone P; George J; Dammers E; Fu M; Kurland D; Lenz O; Ouwerkerk-Mahadevan S; Verbinnen T; Scott J; Jessner W
    Lancet Infect Dis; 2015 Jan; 15(1):27-35. PubMed ID: 25482330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
    Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
    JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
    Meyer-Wyss B; Rich P; Egger H; Helbling B; Müllhaupt B; Rammert C; Gonvers JJ; Oneta C; Criblez D; Rossi L; Borovicka J; Meyenberger C; Arn M; Renner EL;
    J Viral Hepat; 2006 Jul; 13(7):457-65. PubMed ID: 16792539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural killer cell receptor and HLA-C gene polymorphisms among patients with hepatitis C: a comparison between sustained virological responders and non-responders.
    Carneiro VL; Lemaire DC; Bendicho MT; Souza SL; Cavalcante LN; Angelo AL; Freire SM; Mendes CM; Santana N; Lyra LG; Lyra AC
    Liver Int; 2010 Apr; 30(4):567-73. PubMed ID: 20456039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sex-related influence of angiotensin-converting enzyme polymorphisms on fibrosis progression due to recurrent hepatitis C after liver transplantation.
    Fabris C; Toniutto P; Bitetto D; Minisini R; Fornasiere E; Smirne C; Pirisi M
    J Gastroenterol; 2007 Jul; 42(7):543-9. PubMed ID: 17653650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C.
    Fontana RJ; Litman HJ; Dienstag JL; Bonkovsky HL; Su G; Sterling RK; Lok AS;
    Liver Int; 2012 Apr; 32(4):665-74. PubMed ID: 22103814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.
    Sobesky R; Mathurin P; Charlotte F; Moussalli J; Olivi M; Vidaud M; Ratziu V; Opolon P; Poynard T
    Gastroenterology; 1999 Feb; 116(2):378-86. PubMed ID: 9922319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mannan-binding lectin MBL2 gene polymorphism in chronic hepatitis C: association with the severity of liver fibrosis and response to interferon therapy.
    Alves Pedroso ML; Boldt AB; Pereira-Ferrari L; Steffensen R; Strauss E; Jensenius JC; Ioshii SO; Messias-Reason I
    Clin Exp Immunol; 2008 May; 152(2):258-64. PubMed ID: 18336595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is serum angiotensin converting enzyme level a useful non-invasive marker for liver fibrosis in patients with chronic hepatitis C?
    Akar T
    Rev Assoc Med Bras (1992); 2018 Mar; 64(3):224-229. PubMed ID: 29641775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection.
    Wright M; Goldin R; Hellier S; Knapp S; Frodsham A; Hennig B; Hill A; Apple R; Cheng S; Thomas H; Thursz M
    Gut; 2003 Aug; 52(8):1206-10. PubMed ID: 12865283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of CYP2D6 polymorphism in predicting liver fibrosis progression rate in Caucasian patients with chronic hepatitis C.
    Fishman S; Lurie Y; Peretz H; Morad T; Grynberg E; Blendis LM; Leshno M; Brazowski E; Rosner G; Halpern Z; Oren R
    Liver Int; 2006 Apr; 26(3):279-84. PubMed ID: 16584388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B.
    Noguchi R; Kaji K; Namisaki T; Moriya K; Kitade M; Takeda K; Kawaratani H; Okura Y; Aihara Y; Furukawa M; Mitoro A; Yoshiji H
    World J Gastroenterol; 2017 Sep; 23(36):6705-6714. PubMed ID: 29085215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.